Can Molecular Biomarkers Help Reduce the Overtreatment of DCIS?

Abstract

Ductal carcinoma in situ (DCIS), especially in the era of mammographic screening, is a commonly diagnosed breast tumor. Despite the low breast cancer mortality risk, management with breast conserving surgery (BCS) and radiotherapy (RT) is the prevailing treatment approach in order to reduce the risk of local recurrence (LR), including invasive LR, which carries a subsequent risk of breast cancer mortality. However, reliable and accurate individual risk prediction remains elusive and RT continues to be standardly recommended for most women with DCIS. Three molecular biomarkers have been studied to better estimate LR risk after BCS-Oncotype DX DCIS score, DCISionRT Decision Score and its associated Residual Risk subtypes, and Oncotype 21-gene Recurrence Score. All these molecular biomarkers represent important efforts towards improving predicted risk of LR after BCS. To prove clinical utility, these biomarkers require careful predictive modeling with calibration and external validation, and evidence of benefit to patients; on this front, further research is needed. Most trials do not incorporate molecular biomarkers in evaluating de-escalation of therapy for DCIS; however, one-the Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk DCIS (ELISA) trial-incorporates the Oncotype DX DCIS score in defining a low-risk population and is an important next step in this line of research.

Keywords: DCIS; biomarkers; ductal carcinoma in situ.

Figure 1

Cumulative Incidence of Invasive Local Recurrence and Breast Cancer Mortality by Recurrence Score and Treatment. (a) Cumulative incidence function for development of invasive local recurrence as a first event with competing risks of ipsilateral DCIS LR, contralateral breast cancer and death, (b) breast cancer mortality with competing risk of death from other causes. DCIS = ductal carcinoma in situ; LR = local recurrence.